Published Paper Details:

For many years, milk thistle (Silybum marianum) has been used as a herbal cure for a variety of illnesses. A complex blend of flavonolignans, including silibinin (silybin), silychristin, and silidianin, makes up the main active ingredient "SILYMARIN." Research on pharmacology has shown that silymarin possesses strong anti-inflammatory, antifibrotic, and antioxidant characteristics. Mixed results have come from clinical trials examining the effectiveness of milk thistle in treating a variety of liver illnesses, such as liver cirrhosis, hepatitis B and C, non-alcoholic fatty liver disease, and alcoholic liver disease. Because of its well-established safety record and low number of documented side effects, milk thistle is a valuable adjunctive treatment. Silymarin's pharmacokinetics shows that it has limited oral bioavailability and poor water solubility, which make it difficult to employ therapeutically. To improve its absorption and bioavailability, advances in formulation technologies, such as the creation of liposomal, nanoparticles, and phytosomes, have been investigated. The goal of this paper is to give a thorough overview of milk thistle's pharmacological characteristics and pharmacokinetics, as well as its possible application in the treatment of liver illnesses and other ailments such as cancer, viral infection, fibrosis, tumorigenesis, inflammation, etc.